Sequenta
Retrospective Analysis Shows ctDNA Superior to CT Scan for Predicting Relapse in Lymphoma Patients
Premium
The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.
Adaptive hopes to develop a gold standard for immune sequencing using the combined technologies.
Adaptive Biotechnologies Acquires Sequenta
Adaptive Biotechnologies CEO Chad Robins will remain as CEO, and Sequenta CEO Tom Willis and CSO Malek Faham will join the senior leadership team.
Immunosequencing Comes of Age as Researchers Demo Clinical Utility, Aim for FDA-cleared Products
Premium
Researchers are demonstrating that sequencing the immune repertoire can offer valuable insight into blood cancers, treatment response, and the likelihood of relapse.
Sequenta, Illumina Strike IVD Deal for NGS-based Test to Monitor Residual Disease
Sequenta and Illumina have struck an agreement to commercialize an in vitro diagnostic kit based on Sequenta's minimal residual disease detection and quantification technology.
Jun 12, 2014
Apr 8, 2014
Oct 24, 2012
Sequenta Receives CLIA Certification
Dec 14, 2011
Dec 24, 2010